News & Updates
Filter by Specialty:
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
Combination therapy with metformin and thiazolidinedione appears to be the best performing glucose-lowering medication for preventing atrial fibrillation (AF) in patients with type 2 diabetes (T2D), as shown in a study.
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
24 Mar 2023
Coordinated care improves use of CVD-preventive therapies in T2D
A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.
Coordinated care improves use of CVD-preventive therapies in T2D
23 Mar 2023
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
23 Mar 2023
5-ASA maintenance therapy of little help in patients with newly diagnosed CD
Maintenance treatment with 5-aminosalicylates (5-ASA) in patients with newly diagnosed Crohn's disease (CD) does not appear to lead to better outcomes as compared with a watchful waiting approach, according to a study.
5-ASA maintenance therapy of little help in patients with newly diagnosed CD
23 Mar 2023
Response to therapy higher in clinical trial than real-world RCC patients
Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.
Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023
Menopausal hormone therapy use carries increased T2DM risk
The use of menopausal hormone therapy (MHT), including the most prescribed agent tibolone, appears to contribute to an increase in the risk of type 2 diabetes mellitus (T2DM), as shown in a retrospective study.
